About

NDC-1308 For Inducing Remyelination

A new drug with the potential to induce remyelination, the process for restoring and repairing the myelin sheath in demyelinating diseases including multiple sclerosis (MS), transverse myelitis and osmotic demyelination syndrome.

NDC-1308


How the Body Makes Myelin

Oligodendrogenesis: the body’s natural process for forming mature, myelinating oligodendrocytes leading to myelin sheaths. The process start from oligodendrocyte progenitor cells (OPCs) that are located throughout the central nervous system (CNS).

oligodendrogensis picture


NDC-1308 Induces the Body’s Natural System for Oligodendrogenisis

NDC-1308 is currently in late preclinical development, it is designed to address one of the root causes of demyelinating disease by inducing oligodendrocyte progenitor cells (OPCs) – the precursors of oligodendrocytes – to mature into oligodendrocytes, the cells that synthesize and maintain the myelin sheath.



Step 1:
Oligodendrocyte progenitor cells (OPCs) are present but quiescent

NDC-1308
Designed to up-regulate key genes to induce remyelination

Step 2:
Gene activated by NDC-1308
Inducing Oligodendrogenisis

Step 3:
Pre-oligodendrocytes become pre-myelinating oligodendrocytes
Step 4:
Pre-myelinating oligodendrocytes become myelinating oligodendrocytes


A multiple Target Approach

The unique remyelinating activity of NDC-1308 comes from its ability to significantly up-regulate key genes necessary for OPC differentiation into mature oligodendrocytes.

To learn more go to:

About Myelin, Demyelination and Remyelination

NDC 1308 up regulates


ENDECE logo
Developing new drugs for diseases with limited or non-existent treatment options.
TO REQUEST MORE INFORMATION GO TO:
www.endece.com/contact